主要股东
| 股东名称 | 最终控制人 | 持股数(万股) | 占总股本比(%) | 持股变动(万股) | 股票类型 |
|---|---|---|---|---|---|
| 药明合联生物技术有限公司 | 药明生物技术有限公司 | 46885.32 | 60.67 | 不变 | 普通股 |
| 维梧(苏州)健康产业投资基金(有限合伙) | 苏州维梧管理咨询合伙企业(有限合伙) | 6895.92 | 8.92 |
|
普通股 |
持股变动
| 日期 | 股东名称 | 持股变动(万股) | 变动后持股(万股) | 变动后占比(%) | 性质 |
|---|---|---|---|---|---|
| 2026-04-09 | WuXi Biologics (Cayman) Inc. |
|
46885.32 | 60.67 | 好仓 |
| 2026-04-09 | WuXi XDC Cayman Inc. |
|
46885.32 | 60.67 | 好仓 |
| 2026-03-31 | Advantech Capital II L.P. |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Advantech Capital II Master Investment Limited |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Advantech Capital Investment V Limited |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Advantech Capital Partners II Limited |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Golden Sage Investments Limited |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Success Growth Limited |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | 彭其前 |
|
1614.63 | 2.09 | 好仓 |
| 2026-03-31 | Vivo Capital Fund VIII, L.P. |
|
0.00 | 0.00 | 好仓 |
| 2026-03-31 | Vivo Capital LLC |
|
0.00 | 0.00 | 好仓 |
| 2026-03-31 | Vivo Capital VIII, LLC |
|
0.00 | 0.00 | 好仓 |
| 2026-03-31 | WuXi Biologics (Cayman) Inc. |
|
47506.97 | 61.47 | 好仓 |
| 2026-03-31 | WuXi XDC Cayman Inc. |
|
47506.97 | 61.47 | 好仓 |
| 2026-03-24 | Chengwei Evergreen Capital, LP |
|
0.00 | 0.00 | 好仓 |
| 2026-03-24 | Chengwei Evergreen Management, LLC |
|
0.00 | 0.00 | 好仓 |
| 2026-03-17 | WuXi Biologics (Cayman) Inc. |
|
46367.27 | 60.00 | 好仓 |
| 2026-03-17 | WuXi XDC Cayman Inc. |
|
46367.27 | 60.00 | 好仓 |
| 2026-03-12 | Tricor Trust (Hong Kong) Limited |
|
1862.04 | 2.41 | 好仓 |
| 2023-01-10 | 黄纯莹 |
|
952.56 | 1.23 | 好仓 |